Fcγ Receptor IIIb (CD16b) Polymorphisms are Associated with Susceptibility to Idiopathic Pulmonary Fibrosis

• Published in: Lung 2010-12, Vol.188 (6), p.475-481
• Main Authors: Bournazos, Stylianos, Bournazou, Irini, Murchison, John T, Wallace, William A, McFarlane, Pauline, Hirani, Nikhil, Simpson, A. John, Dransfield, Ian, Hart, Simon P
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Case-Control Studies; Chi-Square Distribution; Development and progression; Disease Progression; Fc receptors; Female; Forced Expiratory Volume; Gene Frequency; Genetic aspects; Genetic Predisposition to Disease; GPI-Linked Proteins - genetics; Heterozygote; Homozygote; Humans; Idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - genetics; Idiopathic Pulmonary Fibrosis - immunology; Idiopathic Pulmonary Fibrosis - physiopathology; Immunoglobulin G; Interstitial lung disease; Lung - physiopathology; Male; Medicine; Medicine & Public Health; Middle Aged; neutrophils; Odds Ratio; Phenotype; Pneumology/Respiratory System; Polymerase Chain Reaction; Polymorphism, Genetic; Pulmonary Diffusing Capacity; Pulmonary fibrosis; Receptors, IgG - genetics; Respiratory tract diseases; Risk Assessment; Risk Factors; Scotland; Total Lung Capacity; Vital Capacity
• ISSN: 0341-2040; 1432-1750
• DOI: 10.1007/s00408-010-9262-3

An excess of neutrophils in the alveoli and lung interstitium has been described in idiopathic pulmonary fibrosis (IPF). Engagement of neutrophil Fcγ receptors with IgG complexes may contribute to the pathogenesis of IPF. The neutrophil FcγRIIIb receptor occurs in two codominantly expressed allelic variants, NA1 and NA2, which exhibit different binding affinities for IgG1 and IgG3 subclasses. The aim of this study was to investigate whether FcγRIIIb genotype is associated with IPF susceptibility or disease progression. In a case-control study we compared the distribution of FcγRIIIb NA1/2 polymorphisms in 142 patients with IPF and in 218 controls using allele-specific PCR amplification. Significant skewing in the distribution of FcγRIIIb genotypes was observed between patients with IPF and control subjects. In the IPF cohort, there was higher frequency of the NA1/NA1 genotype (0.19 vs. 0.07), and lower NA2/NA2 frequency (0.31 vs. 0.50; χ² = 17.71, df = 2, P < 0.001). The overall frequency of the NA1 allele was increased in IPF patients compared to controls (0.44 vs. 0.29; P < 0.0001, odds ratio [OR] = 1.93, 95% confidence interval [CI] = 1.42-2.64). Heterozygotes and homozygotes of the NA1 allele were at higher risk of developing IPF (OR = 2.19, 95% CI = 1.40-3.41, P = 0.0005), whereas the NA2 allele was protective against IPF (OR = 0.34, 95% CI = 0.17-0.65, P = 0.0014). There was no association of FcγRIIIb genotype with disease progression as assessed by serial lung function measurements. FcγRIIIb NA1/2 polymorphisms are associated with IPF disease susceptibility. These results support a role for immunological mechanisms contributing to IPF pathogenesis.